Psilocybin is under clinical development by Ceruvia Lifesciences and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Psilocybin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Psilocybin overview

Psilocybin is under investigation for the treatment of obsessive compulsive disorder, cluster headache syndrome, major depressive disorder, nicotine dependence, lyme disease, alcohol use disorder (AUD) and migraine headache. The drug candidate is formulated as capsule and administered by oral route. It is a tryptamine alkaloid which is a psychedelic compound acts by targeting 5hydroxy tryptamine 1A and 2A.

Ceruvia Lifesciences overview

Ceruvia Lifesciences is engaged in research, development and commercialization of neuro transformational medicines to treat neurological and psychiatric disorders. The company is investigating its pipeline programs including NYPRG-101, a non-hallucinogenic analog of LSD against migraine, cluster headache, opioid and alcohol use disorders; and SYNP-101, a synthetic form of psilocybin for the treatment of obsessive compulsive disorder (OCD). It also produces GMP LSD and supply to academic research sites and GMP BOL-148. Ceruvia Lifesciences provide treatments for patients, caregivers, payers and health care providers. The company works in collaboration with Yale University, Usona Institute, The Heffter Research Institute, Clusterbusters and New York University (NYU). Ceruvia Lifesciences is headquartered in Greenwich, Connecticut, the US.

For a complete picture of Psilocybin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.